BioPharma Credit (BPCR) Competitors GBX 0.85 -0.01 (-0.70%) (As of 12/20/2024 12:40 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendInsider Trades BPCR vs. AEET, NBMI, FWD, ASIZ, MAVT, BRIG, CTNA, DRUM, STM, and VLEShould you be buying BioPharma Credit stock or one of its competitors? The main competitors of BioPharma Credit include Aquila Energy Efficiency Trust (AEET), NB Global Monthly Income Fund Ltd GBP (NBMI), Forward Partners Group (FWD), Aberforth Split Level Income ZDP 2024 (ASIZ), Momentum Multi-Asset Value Trust (MAVT), BlackRock Income and Growth (BRIG), Catena Group (CTNA), Drumz (DRUM), STM Group (STM), and Volvere (VLE). These companies are all part of the "asset management" industry. BioPharma Credit vs. Aquila Energy Efficiency Trust NB Global Monthly Income Fund Ltd GBP Forward Partners Group Aberforth Split Level Income ZDP 2024 Momentum Multi-Asset Value Trust BlackRock Income and Growth Catena Group Drumz STM Group Volvere Aquila Energy Efficiency Trust (LON:AEET) and BioPharma Credit (LON:BPCR) are both small-cap financial services companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends, community ranking and institutional ownership. Does the MarketBeat Community believe in AEET or BPCR? BioPharma Credit received 84 more outperform votes than Aquila Energy Efficiency Trust when rated by MarketBeat users. CompanyUnderperformOutperformAquila Energy Efficiency TrustN/AN/ABioPharma CreditOutperform Votes8464.62% Underperform Votes4635.38% Which has preferable earnings & valuation, AEET or BPCR? BioPharma Credit has higher revenue and earnings than Aquila Energy Efficiency Trust. BioPharma Credit is trading at a lower price-to-earnings ratio than Aquila Energy Efficiency Trust, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAquila Energy Efficiency Trust£6.88M6.21£1.56M£0.022,625.00BioPharma Credit£135.74M0.08£108.45M£0.0810.63 Is AEET or BPCR a better dividend stock? Aquila Energy Efficiency Trust pays an annual dividend of GBX 6 per share and has a dividend yield of 11.4%. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 823.5%. Aquila Energy Efficiency Trust pays out 30,000.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit pays out 8,750.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit is clearly the better dividend stock, given its higher yield and lower payout ratio. Does the media favor AEET or BPCR? In the previous week, Aquila Energy Efficiency Trust's average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score. Company Overall Sentiment Aquila Energy Efficiency Trust Neutral BioPharma Credit Neutral Which has more volatility and risk, AEET or BPCR? Aquila Energy Efficiency Trust has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500. Comparatively, BioPharma Credit has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Is AEET or BPCR more profitable? BioPharma Credit has a net margin of 79.90% compared to Aquila Energy Efficiency Trust's net margin of 22.62%. BioPharma Credit's return on equity of 8.10% beat Aquila Energy Efficiency Trust's return on equity.Company Net Margins Return on Equity Return on Assets Aquila Energy Efficiency Trust22.62% 1.82% 2.90% BioPharma Credit 79.90%8.10%4.98% Do insiders & institutionals have more ownership in AEET or BPCR? 83.9% of Aquila Energy Efficiency Trust shares are held by institutional investors. Comparatively, 41.5% of BioPharma Credit shares are held by institutional investors. 9.5% of Aquila Energy Efficiency Trust shares are held by company insiders. Comparatively, 6.2% of BioPharma Credit shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryBioPharma Credit beats Aquila Energy Efficiency Trust on 10 of the 14 factors compared between the two stocks. Ad Crypto 101 MediaThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… Get BioPharma Credit News Delivered to You Automatically Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPCR vs. The Competition Export to ExcelMetricBioPharma CreditAsset Management IndustryFinancial SectorLON ExchangeMarket Cap£10.20M£1.09B£3.73B£1.91BDividend Yield7.73%4.69%4.43%5.45%P/E Ratio10.63803.44418.741,867.09Price / Sales0.081,454.431,744.90393,302.55Price / Cash1.1964.6052.5328.64Price / Book0.011.141.372.81Net Income£108.45M£64.95M£361.47M£155.77M7 Day Performance-1.62%-1.95%-1.62%-2.02%1 Month Performance-3.85%-0.25%0.23%21.67%1 Year Performance-4.06%7.21%9.87%29.76% BioPharma Credit Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPCRBioPharma CreditN/AGBX 0.85-0.7%N/A-2.1%£10.20M£135.74M10.63N/AAEETAquila Energy Efficiency TrustN/AGBX 51-0.6%N/A-6.3%£41.53M£6.88M2,550.00700Gap UpNBMINB Global Monthly Income Fund Ltd GBPN/AGBX 57.50+2.7%N/AN/A£41.02MN/A338.24N/AGap UpFWDForward Partners GroupN/AGBX 29.50flatN/AN/A£39.78M£-22,030,000.00-155.2615High Trading VolumeASIZAberforth Split Level Income ZDP 2024N/AN/AN/AN/A£39.23M£821,000.00-45.18N/AMAVTMomentum Multi-Asset Value TrustN/AGBX 142.50+0.7%N/AN/A£38.97M£-8,390,000.00-459.68N/ABRIGBlackRock Income and GrowthN/AGBX 196-2.0%N/A+6.8%£38.81M£2.55M2,177.78N/ADividend IncreaseNews CoveragePositive NewsCTNACatena GroupN/AN/AN/AN/A£36.86M£883,133.00-68.46133DRUMDrumzN/AGBX 8.75+16.7%N/AN/A£36.73M£56,000.00-875.00N/AGap UpHigh Trading VolumeSTMSTM GroupN/AGBX 61.50flatN/AN/A£35.53M£30.06M3,075.0048,300VLEVolvereN/AGBX 1,600flatN/A+31.1%£35.36M£46.06M1,193.13226 Related Companies and Tools Related Companies Aquila Energy Efficiency Trust Alternatives NB Global Monthly Income Fund Ltd GBP Alternatives Forward Partners Group Alternatives Aberforth Split Level Income ZDP 2024 Alternatives Momentum Multi-Asset Value Trust Alternatives BlackRock Income and Growth Alternatives Catena Group Alternatives Drumz Alternatives STM Group Alternatives Volvere Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:BPCR) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioPharma Credit Please log in to your account or sign up in order to add this asset to your watchlist. Share BioPharma Credit With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
